News & Events
News & Events
February 14, 2023
Regulus Therapeutics Joins PKDOCC-Path is excited to announce that Regulus Therapeutics, Inc. has joined the Polycystic Kidney Disease Outcomes Consortium (PKDOC) as a voting member. Regulus Therapeutics is a biotech company working to deliver life changing medicines to patients with orphan kidney diseases. The programs in their pipeline target kidney diseases of high unmet need, including ADPKD. PKDOC brings together diverse stakeholders from...
February 7, 2023
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Joins PKDOCC-Path is excited to announce that Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) has joined its Polycystic Kidney Disease Outcomes Consortium as a voting member. PKDOC brings together diverse stakeholders from the pharmaceutical industry, academic researchers, foundations, patient advocacy groups, individuals living with PKD, and regulatory agencies from around the world, to develop solutions to accelerate drug development for PKD,...
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.
September 8, 2022
C-Path’s Kristen Swingle Named PresidentSwingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path...
August 26, 2022
Four PKD Reports Published in CJASNC-Path and PKDOC are excited to announce that four reports summarizing Sessions 1, 2, and 3B from the 2021 PKD Regulatory Summit have been published in The Clinical Journal of the American Society of Nephrology (CJASN). Please find the associated links below: Drug Development for Cystic Kidney Diseases Perspectives on Drug Development in Autosomal Recessive...